4.3 Article

LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition

Journal

ONCOTARGET
Volume 7, Issue 23, Pages 33484-33497

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9255

Keywords

factor binding; genome-wide gene expression analysis

Funding

  1. Wilhelm Sander Stiftung
  2. German Cancer Aid / Dr. Mildred Scheel Stiftung
  3. German Research Foundation (DFG)
  4. Gottingen Graduate School of Neurosciences and Molecular Biosciences (GGNB)

Ask authors/readers for more resources

A considerable proportion of the human genome consists of transposable elements, including the long terminal repeats (LTRs) of endogenous retroviruses. During evolution, such LTRs were occasionally inserted upstream of protein-coding genes, contributing to their regulation. We previously identified the LTR12 from endogenous retrovirus 9 (ERV9) as a regulator of proapoptotic genes such as TP63 or TNFRSF10B. The promoter activity of LTR12 is largely confined to the testes, silenced in testicular carcinoma, but reactivated in testicular cancer cells by broad-range histone deacetylase (HDAC) inhibitors. Here we show that inhibition of HDAC1-3 is sufficient for LTR12 activation. Importantly, HDAC inhibitors induce LTR12 activity not only in testicular cancer cells, but also in cells derived from many additional tumor species. Finally, we characterize the transcription factor NF-Y as a mediator of LTR12 promoter activity and HDAC inhibitor-induced apoptosis, in the context of widespread genomic binding of NF-Y to specific LTR12 sequences. Thus, HDAC inhibitor-driven LTR12 activation represents a generally applicable means to induce proapoptotic genes in human cancer cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available